Profile data is unavailable for this security.
About the company
Sansure Biotech Inc is a company mainly engaged in research and development, production and sales of diagnostic reagents and instruments. The Company's diagnostic reagent products are comprised of viral hepatitis series, reproductive tract infection and genetic series, pediatric infection series and nucleic acid blood screening series. The instrument products include automatic nucleic acid detection reaction system construction series and fluorescent polymerase chain reaction (PCR) monitoring and analysis software. The Company also provides related inspection services, including medical inspection and scientific research services which are provided for medical institutions.
- Revenue in CNY (TTM)1.41bn
- Net income in CNY259.42m
- Incorporated2008
- Employees2.01k
- LocationSansure Biotech IncNo.680 Lusong RoadHigh-Tech Industrial Development ZoneCHANGSHA 410205ChinaCHN
- Phone+86 73 188883176
- Fax+86 73 184223503
- Websitehttps://www.sansure.com.cn/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shenzhen YHLO Biotech Co Ltd | 1.90bn | 288.64m | 10.58bn | 1.76k | 36.93 | 3.98 | -- | 5.56 | 0.5026 | 0.5026 | 3.32 | 4.66 | 0.4842 | 1.07 | 4.58 | 1,081,307.00 | 5.85 | 16.43 | 7.46 | 24.16 | 63.98 | 53.26 | 12.08 | 20.01 | 1.28 | 9.13 | 0.2474 | 30.28 | -48.42 | 23.02 | -64.93 | 56.32 | 28.88 | -- |
Shinva Medical Instrument Co Ltd | 10.12bn | 692.34m | 10.92bn | 8.21k | 12.74 | 1.46 | -- | 1.08 | 1.41 | 1.41 | 18.31 | 12.34 | 0.6775 | 2.20 | 4.96 | 1,232,589.00 | 4.72 | 4.63 | 9.14 | 10.76 | 25.62 | 24.22 | 6.96 | 6.12 | 0.8303 | -- | 0.1637 | 15.91 | 7.87 | -0.5342 | 30.78 | 95.70 | -5.90 | 61.86 |
Qingdao Haier Biomedical Co Ltd | 2.24bn | 358.01m | 11.35bn | 2.64k | 31.66 | 2.64 | -- | 5.07 | 1.13 | 1.13 | 7.04 | 13.53 | 0.4018 | 5.12 | 6.38 | 848,473.70 | 6.56 | 11.49 | 8.29 | 15.22 | 47.82 | 49.98 | 16.34 | 25.20 | 2.53 | -- | 0.0316 | 26.53 | -20.36 | 22.07 | -32.41 | 28.94 | 20.64 | -- |
Shandong Weigao Orthopaedic Devce Co Ltd | 1.28bn | 154.60m | 11.78bn | 2.21k | 76.31 | 3.01 | -- | 9.17 | 0.3858 | 0.3858 | 3.20 | 9.78 | 0.2524 | 0.6714 | 4.03 | 581,131.60 | 3.14 | 10.97 | 3.95 | 13.69 | 62.40 | 77.33 | 12.43 | 27.08 | 3.62 | -- | 0.0096 | 17.90 | -30.55 | 1.17 | -79.36 | -19.11 | -4.31 | -- |
Beijing Wandong Medical Technolgy Co Ltd | 1.40bn | 184.09m | 12.02bn | 1.06k | 65.23 | 2.54 | -- | 8.56 | 0.262 | 0.262 | 2.00 | 6.74 | 0.2647 | 2.76 | 4.01 | 1,325,746.00 | 3.50 | 5.30 | 3.91 | 6.21 | 38.83 | 45.21 | 13.22 | 16.46 | 9.48 | -- | 0.0179 | 35.82 | 10.30 | 5.32 | 7.51 | 4.22 | -16.66 | 5.39 |
Shanghai Runda Medical Technology Co Ltd | 8.43bn | 40.27m | 12.83bn | 3.32k | 318.33 | 2.99 | -- | 1.52 | 0.0673 | 0.0673 | 13.61 | 7.17 | 0.5831 | 4.19 | 1.49 | 2,543,990.00 | 1.18 | 4.78 | 3.13 | 12.86 | 25.94 | 27.13 | 2.03 | 6.36 | 1.01 | 3.04 | 0.5609 | 12.43 | -12.84 | 8.93 | -34.58 | 0.8514 | 3.88 | 1.03 |
Shanghai MicroPort Edvcl MdTch Grp CoLtd | 1.27bn | 657.34m | 12.97bn | 908.00 | 19.33 | 3.34 | -- | 10.22 | 5.44 | 5.44 | 10.59 | 31.54 | 0.371 | 1.33 | 6.51 | 1,396,816.00 | 19.00 | 17.68 | 21.55 | 19.43 | 74.51 | 76.60 | 51.21 | 42.25 | 5.49 | -- | 0.0067 | 44.46 | 32.43 | 38.72 | 37.98 | 40.28 | 50.18 | -- |
Sansure Biotech Inc | 1.41bn | 259.42m | 13.37bn | 2.01k | 51.31 | 1.82 | -- | 9.50 | 0.4475 | 0.4475 | 2.44 | 12.62 | 0.1667 | 0.878 | 2.03 | 701,473.70 | 2.52 | 26.74 | 2.79 | 30.97 | 76.43 | 67.47 | 15.12 | 42.01 | 7.45 | -- | 0.0583 | 22.40 | -84.39 | 27.12 | -81.22 | 121.89 | 64.08 | -- |
Micro-Tech Nanjing Co Ltd | 2.68bn | 550.49m | 14.03bn | 2.40k | 25.41 | 3.76 | -- | 5.24 | 2.94 | 2.94 | 14.30 | 19.86 | 0.6118 | 1.65 | 6.80 | 1,114,222.00 | 12.87 | 10.74 | 15.26 | 12.82 | 66.04 | 63.04 | 21.04 | 19.37 | 3.99 | -- | 0.0183 | 35.43 | 21.78 | 21.20 | 46.99 | 20.32 | 39.33 | -- |
Shanghai Haohai Biological Tech Co Ltd | 2.75bn | 430.21m | 14.30bn | 2.16k | 36.54 | 2.83 | -- | 5.20 | 1.86 | 1.86 | 11.89 | 24.07 | 0.3833 | 1.60 | 7.60 | 1,272,966.00 | 5.60 | 4.84 | 6.60 | 5.50 | 68.97 | 72.04 | 14.61 | 16.36 | 3.71 | -- | 0.0697 | 36.86 | 24.59 | 11.24 | 130.58 | 0.0762 | 11.96 | -- |
Data as of Nov 15 2024. Currency figures normalised to Sansure Biotech Inc's reporting currency: Chinese Yuan Renminbi CNY
Holder | Shares | % Held |
---|---|---|
E Fund Management Co., Ltd.as of 30 Sep 2024 | 17.93m | 3.05% |
China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 8.29m | 1.41% |
China Universal Asset Management Co., Ltd.as of 30 Jun 2024 | 6.20m | 1.05% |
Bosera Asset Management Co., Ltd.as of 30 Jun 2024 | 3.22m | 0.55% |
Penghua Fund Management Co., Ltd.as of 30 Jun 2024 | 3.04m | 0.52% |
Wanjia Asset Management Co., Ltd.as of 30 Jun 2024 | 2.37m | 0.40% |
CITIC Securities Co., Ltd. (Invt Port)as of 30 Jun 2024 | 2.30m | 0.39% |
Harvest Fund Management Co., Ltd.as of 30 Jun 2024 | 1.73m | 0.29% |
Maxwealth Fund Management Co., Ltd.as of 30 Jun 2024 | 1.54m | 0.26% |
The Vanguard Group, Inc.as of 02 Oct 2024 | 1.40m | 0.24% |
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.